Fennec Pharmaceuticals Inc. (TSX:FRX)

Market Cap	297.81M
Revenue (ttm)	44.43M
Net Income (ttm)	-20.75M
Shares Out	n/a
EPS (ttm)	-0.76
PE Ratio	n/a
Forward PE	30.69
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136
Average Volume	585
Open	11.33
Previous Close	11.33
Day's Range	11.33 - 11.33
52-Week Range	5.65 - 11.68
Beta	0.40
RSI	69.27
Earnings Date	May 12, 2025

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 32
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: FRX

Financial Performance

In 2024, Fennec Pharmaceuticals's revenue was $47.54 million, an increase of 123.69% compared to the previous year's $21.25 million. Losses were -$436,000, -97.28% less than in 2023.

Financial numbers in USD